Funding Opportunities

Winship researchers receive funding through a variety of awards and grants. View a selection of federal and private funding opportunities for which Winship researchers may be eligible to apply.

ACS Institutional Research Grant Awards

Winship Cancer Institute annually awards one year, non-renewable awards of $30,000 each funded by the American Cancer Society. The American Cancer Society Institutional Research Grants (ACS-IRG) are designed to support the development of beginning investigators conducting cancer research by providing pilot funds to obtain preliminary results that will enable them to compete successfully for national research grants. The program is intended to support independent, self-directed, investigators early in their careers for whom the institution has committed research facilities, resources or space. Applicants must have a faculty level appointment and be within six years of their first independent appointment and no more than 12 years from their last degree. Investigators who have already received peer-reviewed support from the National Institutes of Health, National Science Foundation, American Cancer Society or other major extramural organizations are not eligible.

Letter of Intent Due Date: September 1, 2017

Application Due Date: October 16, 2017

Winship Invest$

Winship Invest$ is a peer-reviewed program providing pilot funding for novel, innovative cancer research projects. The summer 2017 opportunity is focused on the growth and development of Winship’s four research programs, in addition to breast cancer-related research. Proposals with one-year budgets of up to $50,000 may be considered. The highest scored proposal across those selected for funding will receive the Fadlo R. Khuri Translational Research Scholar Award in recognition of outstanding and transformative science.

Eligibility

  1. Pilot projects will be awarded to active Winship members.
  2. Winship members will qualify for only one pilot project grant in a given year and may not submit more than one proposal through this RFP.
  3. Salary support for the principal investigator is not allowed except for junior faculty at the rank of Assistant Professor and below.
  4. All proposals must include a clear plan for subsequent extramural grant submissions as a result of the work proposed.
  5. Data Management - Proposals must include a plan to maintain research data in Redcap or other secure data management system (if relevant) with quality control and stored on the Emory system with back-up and potential for data sharing. Consultation for data sharing plans with the Winship Research Informatics Shared Resource are recommended.
  6. Clinical Research proposals can only be submitted by MDs, MD/PhDs, or RN/PhDs and must include:
    • A Human Subjects Research document
    • Winship CTRC Application
    • Clinical Protocol and Informed Consent Form
    • A plan to maintain clinical research data in OnCore or through the support of the Winship Informatics Shared Resource
    • All clinical research awardees are expected to follow clinical research guidelines set by Emory IRB, Winship Clinical Trials SOPs and the Winship Clinical and Translational Research Committee, and must satisfy clinical research training requirements.
  7. Proposals which include in vivo studies must include a:
    • Section addressing Vertebrate Animals research;
    • IACUC protocol (draft to be submitted or IACUC-approved protocol)
  8. Members receiving funding are expected to submit annual progress reports.

Letter of Intent Due Date: August 4, 2017
Application Due Date: October 6, 2017
Anticipated Start Date: January 1, 2018

Rally Foundation for Childhood Cancer Research Grants

Rally Foundation for Childhood Cancer Research raises awareness and funds for childhood cancer research to find better treatments with fewer long-term side effects and, ultimately, cures.
Rally funds research in the following areas:
  • Under-studied cancer types
  • Innovative approaches to childhood cancer research which could lead to advanced studies or clinical trials
  • Studies that are likely to lead to a clinical trial, personalized, alternative, or integrated research proposals
  • Quality of life and survivorship research proposals
Award Categories
  • Fellowship Grants – Grants are for one or two years support. At the end of the award you may apply for additional funding the next grant cycle. Each funded grant will be awarded up to $50,000 per year.
  • Young Investigator and Independent Investigator Research Grants – Grants are for one or two years support. At the end of the award you may apply for additional funding the next grant cycle. Each funded grant will be awarded up to $50,000 per year.
  • Consortium Grants (three of more institutions collaborating on a grant-supported research project) – Grants are for one or two years support. At the end of the award you may apply for additional funding the next grant cycle. Each funded grant will be awarded up to $100,000 per year.
Eligibility
All academic ranks, Instructor to Professor, with MD, PhD, and/or MD, PhD degree may apply. Principle Investigators need not be U.S. citizens.

Letter of Intent Application Due Date: October 12, 2017
Full Application (invitation only) Due Date: January 10, 2018

Understanding, Preventing, and Managing Immunotherapy-related Adverse Events

The American Cancer Society and the Melanoma Research Alliance have partnered to support research leading towards reduction of immune-related adverse events and improvement of overall outcomes for cancer patients treated with checkpoint immunotherapy. This request for applications offers funding for grants to test feasibility and generate preliminary data in the form of Pilot Awards and at least one Multidisciplinary Team Award. The Melanoma Research Alliance and American Cancer Society have each committed $1 million, which will be used to fund at least one Multidisciplinary Team Award at $1 million for up to three years and up to five pilot awards at $200,000 each for two-year periods. Team Awards are designed to foster interdisciplinary collaborative research to promote transformational advances with the potential for rapid clinical benefit. Pilot Awards are intended to help seed the ground in this relatively young area of checkpoint immune-related adverse events research.

Eligibility

Team Award Eligibility: The Lead PI, Team Principals and Team Investigators must hold a doctorate degree (MD, PhD, or equivalent), be independent and have a full-time faculty position or equivalent at a college, university, medical school, or other fiscally responsible not-for-profit research organization within the United States. There are no citizenship restrictions. Multiple PIs or Co-PIs are not allowed. Early Career Team Investigators within the first 5 years of initial faculty appointment may serve as a Team Investigator. Early Career Team Investigators may not serve as the Lead PI.

Pilot Award Eligibility: Independent investigators at all stages of their career are eligible to apply. Principal investigators(PI) must hold a doctorate degree (MD, PhD, or equivalent) and have a full-time faculty position or equivalent at a college, university, medical school, or other not-for-profit organization within the United States. Multiple PIs or Co-PIs are not allowed.

Electronic Application Due Date: October 31, 2017
Paper Application Copy Due Date: November 1, 2017

Fanconi Anemia Research Fund Grants

The Fanconi Anemia Research Fund seeks to improve the lives of individuals with Fanconi anemia through research that focuses on the rapid discovery and development of therapies or strategies that treat, control, or cure Fanconi anemia.

Fanconi is interested in supporting interdisciplinary and translational research efforts that effectively address one or more of the following priorities:
  • To understand how alteration of the Fanconi anemia genes and their products lead to the clinical manifestations of Fanconi anemia.
  • To determine the causes of bone marrow failure, myelodysplasia and leukemia in individuals with Fanconi anemia, and to develop strategies to prevent, treat, and cure these disorders.
  • To define the pathogenesis of Fanconi anemia-associated cancers, and to develop strategies for prevention, early detection, treatment and cure.
  • To identify practical and proactive management strategies that families and persons with Fanconi anemia can use to maintain a high quality of life.
  • To support the creation of shared resources, databases, and technologies for the international Fanconi anemia research community.

A Letter of Intent (LOI) is required for research funding consideration. The LOI is limited to one page and must include (1) Specific Aims, (2) Lay Abstract, (3) Total Funds Requested and (4) Translatable Applicability. A submitted LOI longer than one page will be returned.

Letter of Intent Due Date: October 13, 2017
Investigator Informed of Decision: November 3, 2017
Grant Submission Due Date: February 2, 2018
Investigator Informed of Decision: June 29, 2018
Earliest Project Start Date: August 1, 2018

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery

The Behavioral Research Program, Epidemiology and Genomics Research Program, and Healthcare Delivery Research Program of the National Cancer Institute’s Division of Cancer Control and Population Sciences have collaborated on the release of a program announcement to study the utilization, adherence, and delivery of oral anticancer agents.  Specifically, this program announcement encourages research grant applications to:

  1. Assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; 
  2. Identify structural, systemic, and psychosocial barriers to adherence; and 
  3. Develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.   

PA-17-060 (R01)
PA-17-061 (R21)

Standard application due dates apply.

Cascade Link  TOP